UVA Investigator-initiated Trials (single- and multi-site)

  • A phase I/II trial of long peptide vaccine plus TLR agonists (Mel 60) (NCT02126579).
  • Optimal dose finding study of ABT-199 and ibrutinib in MCL (ABT-199) (NCT02419560).
  • Focused ultrasound therapy to augment antigen presentation and immune-specificity of checkpoint inhibitor therapy with pembrolizumab in metastatic breast cancer (Breast 48) (NCT03237572)
  • A pilot study of the combination of entinostat with capecitabine in high risk breast cancer after neo-adjuvant therapy (Breast 49) (NCT03473639).
  • Phase I study of inotuzumab with augmented BFM re-Induction for younger adults with relapsed/refractory B-cell ALL (NCT03962465)
  • Melanoma vaccine against neoantigen and shared antigens by CD40 activation and TLR agonists in patients with melanoma (Mel66) (NCT04364230)
  • Prospective trial of combination external beam radiation therapy and MRI-guided, dose-differentiated high dose-rate prostate brachytherapy boost for unfavorable-intermediate and high-risk prostate cancer (Prostate-005) (NCT04465500)
  • Pilot evaluation of focused ultrasound ablation and focused ultrasound ablation plus PD-1 antibody blockade in advanced solid tumors (AM-003) (NCT04116320)

External Collaborations

  • Adjuvant hypofractionated whole pelvis radiation therapy in endometrial cancer (NCT04458402) [University of Cincinnati].

External Consultations

  • University of Kentucky
  • Mayo Clinic
  • University of Miami
  • Duke University
  • University of Pennsylvania
  • Columbia University
  • Johns Hopkins University
  • Memorial Sloan Kettering Cancer Center
  • Medical University of South Carolina
  • St. Jude Children’s Hospital
  • Nagoya University (Japan)
  • Pfizer Inc.
  • Boehringer Ingelheim Pharmaceuticals
  • Eli Lilly & Company
  • Onyx Pharmaceuticals